Original Research Articles
Morder KM, Nguyen M, Wilfahrt DN, Dahmani ZL, Burr AB, Xie B, Morikone M, Nieves-Rosado H, Gunn WG, Hurd DE, Wang H, Mullett SJ, Bossong K, Gelhaus SL, Rajasundaram D, Kane LP, Delgoffe GM, Das J, Davar D, Overacre-Delgoffe AE. “Sucralose consumption ablates cancer immunotherapy response through microbiome disruption.” Cancer Discov. 2025 Jul 30. doi: 10.1158/2159-8290.CD-25-0247. Epub ahead of print. PMID: 40742298.
Overacre-Delgoffe AE, Bumgarner HA, Cillo AR, Burr AHP, Tometich JT, Tabib T, Lafyatis R, Vignali DAA, Hand TW. “Microbiota-specific T cells drive tertiary lymphoid structures and anti-tumor immunity in colorectal cancer.” Immunity. 2021. Dec 14. doi: 10.1016/j.immuni.2021.11.003.
Overacre-Delgoffe AE, Chikina M, Dadey RE, Yano H, Brunazzi EA, Shayan G, Horne W, Moskovitz JM, Kolls JK, Sander C, Shuai Y, Normolle DP, Kirkwood JM, Ferris RL, Delgoffe GM, Bruno TB, Workman CJ, Vignali DAA. “Interferon-γ drives Treg fragility to promote anti-tumor immunity.” Cell. 2017 June 1;169(6):1130-1141. doi: 10.1016/j.cell.2017.05.005.
Reviews
Patra D, Dev G, Hand TW, Overacre-Delgoffe A. “Friends close, enemies closer: the complex role of the microbiome in antitumor immunity.” Curr Opin Immunol. 2025 Apr;93:102537. doi: 10.1016/j.coi.2025.102537. Epub 2025 Feb 27. PMID: 40015179.
Anderson KG, Braun DA, Buqué A, Gitto SB, Guerriero JL, Horton B, Keenan BP, Kim TS, Overacre-Delgoffe A, Ruella M, Triplett TA, Veeranki O, Verma V, Zhang F. “Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies.” J Immunother Cancer. 2023 Jun;11(6):e006533. doi: 10.1136/jitc-2022-006533. PMID: 37399356; PMCID: PMC10314654.
Hand, TW and Overacre-Delgoffe, AE. “The complex immunological role of Helicobacter in modulating cancer.” Trends in Immunology. 2022 Oct. doi: 10.1016/j.it.2022.08.002.
Overacre-Delgoffe AE, Hand TW. “Regulation of tissue-resident memory T cells by the Microbiota.” Mucosal Immunol. 2022 Mar;15(3):408-417. doi: 10.1038/s41385-022-00491-1. Epub 2022 Feb 22. PMID: 35194180; PMCID: PMC9063729.
Marron TU, Ryan AE, Reddy SM, Kaczanowska S, Younis RH, Thakkar D, Zhang J, Bartkowiak T, Howard R, Anderson KG, Olson D, Naqash AR, Patel RB, Sachdev E, Rodríguez-Ruiz ME, Sheffer M, Church SE, Fuhrman C, Overacre-Delgoffe AE, Nguyen R, Florou V, Thaxton J, Aggen DH, and Guerriero JL. “Considerations for treatment duration in responders to immune checkpoint inhibitors.” JITC. 2021 Mar;9(3):e001901. doi: 10.1136/jitc-2020-001901.
Overacre-Delgoffe AE, Vignali, DA. “Treg fragility: a prerequisite for effective anti-tumor immunity?” Cancer Immunology Research. 2018 Aug;6(8):882-887. doi: 10.1158/2326-6066.
Overacre AE, Vignali, DA. “Treg stability: to be or not to be?” Curr Opin Immunol. 2016 April;39:39-43. doi: 10/1016/j.coi.2015.12.009.
Overacre AE, Kurtulus S, Sznol M, Pardoll D, Anderson A, Vignali DA. “Combination immunotherapy: Where do we go from here?” JITC. 2015 Aug 3:38.
Collaborative Research
Coombs RS, Overacre-Delgoffe AE, Bhattacharjee A, Hand TW, Boyle JP. “Mouse innate resistance to Neospora caninum infection is driven by early production of IFNγ by NK cells in response to parasite ligands.” mSphere. 2024 Nov 21;9(11):e0025524. doi: 10.1128/msphere.00255-24. Epub 2024 Oct 24. PMID: 39445806; PMCID: PMC11580461.
Burr AHP, Ji J, Ozler K, Mentrup HL, Eskiocak O, Yueh B, Cumberland R, Menk AV, Rittenhouse N, Marshall CW, Chiaranunt P, Zhang X, Mullinax L, Overacre-Delgoffe A, Cooper VS, Poholek AC, Delgoffe GM, Mollen KP, Beyaz S, Hand TW. “Excess Dietary Sugar Alters Colonocyte Metabolism and Impairs the Proliferative Response to Damage.” Cell Mol Gastroenterol Hepatol. 2023;16(2):287-316. doi: 10.1016/j.jcmgh.2023.05.001. Epub 2023 May 11. PMID: 37172822; PMCID: PMC10394273.
Bhattacharjee A, Burr AB, Overacre-Delgoffe AE, Tometich JT, Yang D, Huckestein BR, Linehan JL, Spencer SP, Hall JA, Harrison OJ, Morais da Fonseca D, Norton EB, Belkaid Y, Hand TW. “Environmental enteric dysfunction induces regulatory T cells that inhibit local CD4+ T cell responses and impair oral vaccine efficacy.” Immunity. 2021. Aug 10. doi: 10.1016/j.immuni.2021.07.005.
Watson MJ, Vignali PDA, Mullett SJ, Overacre-Delgoffe AE, Peralta R, Grebinowski S, Menk AV, Rittenhouse NL, DePeaux K, Whetstone RD, Vignali DAA, Hand TW, Poholek AC, Morrison BM, Rothstein JD, Wendell SG, Delgoffe GM. “Metabolic support of tumor-infiltrating regulatory T cells by lactic acid.” Nature. 2021 Feb 15. doi: 10.1038/s41586-020-03045-2.
Chuckran CA, Cillo AR, Moskovitz J, Overacre-Delgoffe AE, Somasundaram AS, Magnon GC, Abecassis I, Zureikat AH, Luketich J, Pennathur A, Sembrat J, Rojas M, Merrick DT, Taylor SE, Orr B, Modugno F, Bukanovich R, Schoen RE, Kim S, Duvvuri U, Zeh H, Edwards R, Kirkwood JM, Coffman L, Ferris RL, Bruno TC, Vignali DAA. “Neuropilin-1 enforces human regulatory T cell stability and function in solid tumors.” Science Translational Medicine. In press. 2021.
Delgoffe GM*, Woo SR*, Turnis ME, Guy CS, Gravano DM, Overacre AE, Bettini ML, Finkelstein DF, Vogel P, Workman CJ and Vignali DA. “Stability and function of regulatory T cells is maintained by a neuropilin-1–semaphorin-4a axis.” Nature. 2013 Sep 12;501(7466):252-6. doi:10.1038/nature12428.
Guy CS, Vignali KM, Temirov J, Bettini ML, Overacre AE, Smeltzer M, Zhang H, Huppa JB, Tsai YH, Lobry C, Xie J, Dempsey PJ, Crawford HC, Aifantis I, Davis MM, Vignali DA. “Distinct TCR signaling pathways drive proliferation and cytokine production in T cells.” Nat Immunol. 2013 Mar;14(3):262-70. doi: 10.1038/ni.2538.
